BAX

Baxter International has shown early signs of a turnaround, with improving execution and raised revenue guidance supporting cautious optimism. BAX's valuation has expanded from distressed levels, now trading at ~13x earnings and ~9.5x EV/EBITDA, yet remains attractive if growth continues. Management's focus on operational improvements, cost savings, and a conservative outlook suggests potential for further upside if EPS growth materializes.

Baxter beats second-quarter earnings and revenue estimates, posts broad-based segment growth and raises its 2026 outlook despite margin pressure.

Baxter International Inc. (BAX) Q2 2026 Earnings Call Transcript

The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Baxter International (BAX) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.59 per share a year ago.

Medical products maker Baxter International on Thursday raised its annual profit forecast and beat Wall Street estimates for quarterly ​results, banking on robust sales of its medical ‌products such as IV solutions.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2026. “Our second-quarter results exceeded expectations on both the top and bottom lines, driven by both operating performance and an additional benefit from a tariff refund that was not previously contemplated in our guidance,” said Andrew Hider, president and CEO. “While we're encouraged by this steady progress and core operating momentum, we remain.

Medical product makers face Q2 margin pressure from tariffs and inflation even as demand stays strong. See which earnings reports could surprise.

BAX's second-quarter results may reflect pressured earnings and sales as manufacturing inefficiencies, inflation, and product holds offset steady demand across segments.

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.